In the Canadian Cancer Trials Group CO.26 study, MSS colorectal cancer patients with elevated plasma TMB levels (≥28 muts/Mb) showed predictable responses to the combination therapy of the anti-PD-L1 drug durvalumab and the anti-CTLA4 drug tremelimumab [43]. The gene discussed is CTLA4; the disease is colorectal cancer.